Navigation Links
BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
Date:11/10/2008

LAVAL, QC, Nov. 10 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) reports results for the third quarter ended September 30, 2008. For the three-month period ended September 30, 2008, the net loss amounted to $11,095,000 ($0.22 per share), compared to $13,889,000 ($0.29 per share) for the corresponding period the previous year. For the nine-month period ended September 30, 2008, the net loss amounted to $36,703,000 ($0.74 per share), compared to $65,389,000 ($1.54 per share) for the same period last year.

The net loss for the current third quarter included net sales of $153,000 which represents one month of sales of VIVIMIND(TM), the Company's first natural health brand launched in Canada and on the Internet on September 2, 2008. The net loss for the nine-month period ended September 30, 2007, included a non-cash accretion expense under Canadian GAAP of $10,430,000 relating to the $40 million 5% senior subordinated convertible notes issued in May 2007.

Research and development expenses, before research tax credits and grants, amounted to $5,208,000 for the current quarter ($21,111,000 for the nine-month period), compared to $11,964,000 for the same period the previous year ($43,533,000 for the nine-month period). The decrease in the current periods compared to the same periods the previous year is mainly attributable to a reduction in expenses incurred in relation to the development of tramiprosate (ALZHEMED(TM); homotaurine) for the treatment of Alzheimer's disease, following the Company's decision in November 2007 to terminate the tramiprosate (ALZHEMED(TM)) pharmaceutical drug development program.

As at September 30, 2008, the Company had available cash, cash equivalents and marketable securities of $20,595,000, compared to $58,672,000 at December 31, 2007. The decrease is primarily due to funds used in operating activities.

Eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis

With
'/>"/>

SOURCE BELLUS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine news :

1. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
2. BELLUS Health provides update on activities
3. BELLUS Health announces closing of Innodia acquisition
4. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
5. BELLUS HEALTH reports results for first quarter of fiscal 2008
6. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
7. Healthcare Realty Trust Announces Third Quarter Results
8. World Publics See Government as Responsible for Ensuring Basic Healthcare, Food, and Education Needs
9. MAP Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
10. Major Mental Health Associations Join to Support Give an Hour
11. Wyeth to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium ... day each year is the Super Bowl. In the two weeks that separate the conference ... host venue. The 2016 Super Bowl game will mark the 50th time it has been ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted ... in predictive health analytics , Jvion continues to disrupt the predictive analytic ... software that targets patient and population level illness to drive prevention and better ...
(Date:7/31/2015)... ... 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of ... Aesthetics released this new applicator in the United States as an upgrade to the ... The original applicator required a 2 hour treatment time. The new CoolSmooth ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin ... re-branded their social media profiles to better connect with the public. The agency ... find information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to ...
(Date:7/31/2015)... ... 2015 , ... Ticket Down is a reliable source of authentic Hamilton ... and refreshing show on Broadway, look no further than Hamilton. This American musical is ... Critics Circle Award, Drama Desk Award, Lucille Lortel Award, and New York Drama Critics’ ...
Breaking Medicine News(10 mins):Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7
... SAINT LOUIS, Sept. 24 Accelify announced today ... District (SLPS) voted unanimously to approve the selection of Accelify ... serves approximately 25,000 students making it the largest school district ... Accelify was among a number of companies who responded to ...
... , , WASHINGTON, ... and increased blood pressure in men released yesterday by the ... fructose with high fructose corn syrup, erroneously suggesting that they ... "It is important not to treat studies involving massive ...
... N.J., Sept. 24 Marketing Technology Solutions , ... QualityHealth.com , has today filed a lawsuit alleging that ... misappropriated trade secrets and other confidential information by utilizing MTS-copyrighted online ... a health website owned and operated by MediZine. , , ...
... ... 140 characters or less from change:healthcare , a healthcare technology company. Which is ... proposing. , ... September 24, 2009 -- Starting today, consumers can simply tweet healthcare questions such as "what ...
... , , IRVINE, Calif., Sept. 24 ... the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse ... (GPO) for home care providers, jointly announce a preferred supplier agreement ... SET Pulse Oximeters and sensors. Masimo,s solutions are proven to ...
... , , , ... QRxPharma Limited (ASX: QRX and Pink Sheets: QRXPY), announced ... ("Nuokang"), a Chinese biopharmaceutical company based in Shenyang, China, to ... The strategic alliance involves Nuokang investing US$5.0 million for ...
Cached Medicine News:Health News:Saint Louis Public School District Awards Contract to Accelify 2Health News:Corn Refiners Association Comments on Findings in Recent Report on Sugars and High Blood Pressure 2Health News:MediZine Named in Intellectual Property Lawsuit Filed by Marketing Technology Solutions 2Health News:change:healthcare Announces Twitter Application that brings Healthcare Information and Costs to Consumers' Fingertips 2Health News:change:healthcare Announces Twitter Application that brings Healthcare Information and Costs to Consumers' Fingertips 3Health News:The MED Group Signs Preferred Supplier Agreement for Masimo SET(R) Pulse Oximetry Solutions 2Health News:The MED Group Signs Preferred Supplier Agreement for Masimo SET(R) Pulse Oximetry Solutions 3Health News:The MED Group Signs Preferred Supplier Agreement for Masimo SET(R) Pulse Oximetry Solutions 4Health News:The MED Group Signs Preferred Supplier Agreement for Masimo SET(R) Pulse Oximetry Solutions 5Health News:QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets 2Health News:QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets 3Health News:QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets 4
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 /PRNewswire/ ... Co., Ltd. (Headquarters: Tokyo , President ... Therapeutics, Inc. (Headquarters: San Diego, California ... "NASDAQ: HALO") have signed a clinical collaboration agreement to ... "eribulin") in combination with Halozyme,s investigational drug PEGPH20 (PEGylated ...
(Date:7/31/2015)... , July 31, 2015 According ... Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry ... Weighing) - Global Analysis & Forecast to 2019", published ... pegged at $911.1 Million 2014 and is estimated to ... CAGR of 9.4% from 2014 to 2019. ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
... a comprehensive, authoritative drug reference to ... overdose management, Canadian drug names, OTC ... drug references and tools is included ... (ED, PRIMARY CARE PLUS, CRC, RN, ...
... patients and health consumers from the trusted ... in MedMaster includes why the medication is ... side effects and warning signs of adverse ... information on what to do if a ...
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Medicine Products: